Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Neoadjuvant Treatment in Rectal Cancer
NCT00330915Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in rectal cancer, sponsored by Eli Lilly and Company. Primary endpoint: Feasibility of Pemetrexed Prior to Surgery. Started Jun 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00330915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330915.